Expanding the Knowledge of KIF1A-Dependent Disorders to a Group of Polish Patients

Genes (Basel). 2023 Apr 25;14(5):972. doi: 10.3390/genes14050972.

Abstract

Background: KIF1A (kinesin family member 1A)-related disorders encompass a variety of diseases. KIF1A variants are responsible for autosomal recessive and dominant spastic paraplegia 30 (SPG, OMIM610357), autosomal recessive hereditary sensory and autonomic neuropathy type 2 (HSN2C, OMIM614213), and autosomal dominant neurodegeneration and spasticity with or without cerebellar atrophy or cortical visual impairment (NESCAV syndrome), formerly named mental retardation type 9 (MRD9) (OMIM614255). KIF1A variants have also been occasionally linked with progressive encephalopathy with brain atrophy, progressive neurodegeneration, PEHO-like syndrome (progressive encephalopathy with edema, hypsarrhythmia, optic atrophy), and Rett-like syndrome.

Materials and methods: The first Polish patients with confirmed heterozygous pathogenic and potentially pathogenic KIF1A variants were analyzed. All the patients were of Caucasian origin. Five patients were females, and four were males (female-to-male ratio = 1.25). The age of onset of the disease ranged from 6 weeks to 2 years.

Results: Exome sequencing identified three novel variants. Variant c.442G>A was described in the ClinVar database as likely pathogenic. The other two novel variants, c.609G>C; p.(Arg203Ser) and c.218T>G, p.(Val73Gly), were not recorded in ClinVar.

Conclusions: The authors underlined the difficulties in classifying particular syndromes due to non-specific and overlapping signs and symptoms, sometimes observed only temporarily.

Keywords: HSN2C; KIF1A; NESCAV; SPG30; children; neurodegeneration.

MeSH terms

  • Atrophy
  • Female
  • Humans
  • Infant
  • Kinesins / genetics
  • Male
  • Neurodegenerative Diseases*
  • Poland
  • Spasms, Infantile*
  • Spastic Paraplegia, Hereditary* / pathology

Substances

  • Kinesins
  • KIF1A protein, human

Grants and funding

This research received no external funding.